Media

C4X Discovery Holdings plc

("C4XD" or the "Company")

C4X Discovery collaboration with E-Therapeutics identifies new pathophysiological mechanisms in Parkinson’s disease

Early results point to novel approaches to drug discovery for this debilitating disease

Manchester and Oxford, UK, 6 December 2018: C4X Discovery Holdings plc (C4X.L) ("C4XD") and e-therapeutics plc (AIM: ETX, "e-therapeutics"), the network-driven drug discovery (NDD) company, are pleased to announce an update on their collaboration (announced 1st May 2018) to identify novel intervention strategies for the potential treatment of Parkinson’s Disease (PD).

C4X Discovery Holdings plc

("C4XD" or the "Company")

C4XD enters discovery partnership with state-of-the-art artificial intelligence company, GTN Ltd.

Partnership to maximise insights from shape-based chemistry and generate novel drug candidates in neurodegeneration

29 November 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a drug discovery partnership with GTN Ltd. (“GTN”), a disruptive new player in the field of drug discovery artificial intelligence (“AI”), initially focussing on identifying potential small molecule hits against a high-value neurodegeneration target.

C4X Discovery Holdings plc

("C4XD" or the "Company")

LifeArc and C4X Discovery join forces to develop small molecule drug candidates active against a high value, novel oncology and inflammation target

27 November 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that it has entered into a discovery partnership with LifeArc®, one of the UK’s leading medical research charities. C4XD and LifeArc will join forces to progress medicinal chemistry efforts on a novel, commercially attractive programme with applicability across oncology and inflammation indications. The undisclosed target originated from LifeArc’s extensive partnerships in early-stage academic research.

This announcement contains inside information

C4X Discovery Holdings plc

("C4XD" or the "Company")

Full year results for the year ended 31 July 2018

21 November 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its full year results for the year ended 31 July 2018.

Friday, 09 November 2018

Notice of Results

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Notice of Results

9 November 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, will be announcing its full year results for the year ended 31 July 2018 on Wednesday 21 November 2018.

A webcast and conference call for analysts will be held at 11:30am GMT on the day of the results. Presentation slides will be made available on the Company website in advance of the call.

C4X Discovery Holdings plc

(“C4XD” or the “Company”)

 

Result of General Meeting and Open Offer
and
Issue of Equity

 

5 October 18 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that at the General Meeting held earlier today in connection with the Company’s Placing and Open Offer at a price of 90 pence per new Ordinary Share, details of which were announced on 18 September 2018, all resolutions put to shareholders were duly passed.

Tuesday, 18 September 2018

Results of Placing

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

Results of Placing

18 September 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, is pleased to announce the completion of the Placing announced earlier today.

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

Proposed Placing and Open Offer

Proceeds of fundraise will support the Company’s strategy of becoming the world’s most productive, self-sustaining drug discovery engine

18 September 2018 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces a proposed conditional Placing of Placing Shares with existing and new institutional investors to raise up to approximately £10.0 million before expenses at the Issue Price of 90 pence per new Ordinary Share.